The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience - 19/08/11
Abstract |
Objective |
This study was undertaken to evaluate the role of secondary cytoreduction in patients with recurrent epithelial ovarian cancer.
Study design |
Secondarily, cytoreduced patients were retrospectively analyzed with respect to the clinicopathologic variables.
Results |
A total of 64 patients were evaluated in this report. Multivariable analysis revealed 3 factors to be significant: optimal cytoreduction during primary (P = .003, odds ratio [OR]: 0.30; 95% CI: 0.14-0.66), secondary cytoreduction (P = .04, OR: 0.47; 95% CI: 0.22-0.99), and the endometrioid histologic type (P = .005, OR: 0.09; 95% CI: 0.02-0.48). Intrinsic factors of the tumors (grade, stage, age), size, and number of recurrent tumors were nonsignificant.
Conclusion |
Secondary cytoreductive surgery should be offered in selected recurrent epithelial ovarian cancer patients. Further prospective randomized series are needed to determine specific recommendations.
Le texte complet de cet article est disponible en PDF.Key words : Epithelial ovarian carcinoma, Recurrent ovarian carcinoma, Secondary cytoreduction, Optimal debulking
Plan
Reprints not available from the author. Address correspondence to Dr Murat Gultekin. |
Vol 194 - N° 1
P. 49-56 - janvier 2006 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?